SOURCE: PCI Synthesis

PCI Synthesis

April 19, 2016 10:31 ET

PCI Synthesis Announces the Addition of Its cGMP Advanced Polymer Development and Manufacturing Group

The Team Has Experience With Developing Polymeric Materials for Implantable Medical Devices, Drug Delivery Technologies, Therapeutics, Excipients and Medical-Grade Coatings

NEWBURYPORT, MA--(Marketwired - Apr 19, 2016) - PCI Synthesis, Inc. (www.pcisynthesis.com), a drug substance manufacturer of new chemical entities (NCEs) and generic active pharmaceutical ingredients (APIs), today announced the formation of its cGMP Advanced Polymer Development and Manufacturing Group, which is currently developing and manufacturing more than a dozen advanced polymer-based projects. As the largest independent cGMP contract manufacturing organization (CMO) in New England, the addition of an advanced polymer-based materials development and manufacturing capability significantly expands the company's customer base and reach within this growing market.

The team currently includes several Ph.D.-level polymer chemists with broad expertise in the development, scale up, and eventual cGMP manufacturing of these important materials. The team is also supported by PCI Synthesis's existing and well-respected Kilo Lab team. Products in development include a broad range of polymer-based materials, including:

  • Implantable medical devices including biodegradable implants.
  • Nano-polymer particle technology.
  • Combination API and polymer technologies.
  • Drug delivery technologies.
  • Therapeutics and excipients.
  • Medical-grade coatings.

The PCI Synthesis Advanced Polymer Manufacturing Group operates out of the company's development lab in Devens, Mass., and collaborates with its cGMP facilities in Newburyport, Mass.

"PCI Synthesis is the only CMO in Massachusetts doing this kind of advanced cGMP polymer manufacturing, which is a big advantage for local life sciences and pharma firms, since we're able to collaborate with them and their projects onsite. Advanced polymer manufacturing projects require sophisticated analytical techniques, and it is difficult to find that level of expertise," said Ed Price, president and CEO of PCI Synthesis. "All of the projects we undertake begin in our laboratories enabling our teams to not only improve many of our polymerization processes, but also to adopt the latest analytical techniques to support the manufacturing of cGMP polymer materials from kilos to tons. In addition, PCI is the only CMO in North America that can simultaneously develop and manufacture in one organization both the API and any polymer based technology that may be required for combination products which are becoming more and more prevalent for pharmaceutical development."

About PCI Synthesis
PCI Synthesis is a Pharmaceutical Development CMO (Contract Manufacturing Organization) based in Newburyport, MA and is the largest small molecule drug substance manufacturer in the New England area. PCI is also a commercial manufacturer of new chemical entities (NCEs), generic active pharmaceutical ingredients (APIs), and other specialty chemical products for the medical device industry. As a contract manufacturing organization (CMO), PCI provides emerging and mid-sized pharmaceutical companies access to the expertise needed to develop and manufacture complex small molecules. To learn more about PCI Synthesis, its proprietary NCE development activities and process R&D capabilities please visit www.pcisynthesis.com.

Contact Information

  • Contact:
    Linda Pendergast-Savage
    Birnbach Communications
    508-224-7905
    Email Contact